Ipr1 modified BCG as a novel vaccine induces stronger immunity than BCG against tuberculosis infection in mice

Wang,Yuwei; Yang,Chun; He,Yonglin; Zhan,Xingxing; Xu,Lei

doi:10.3892/mmr.2016.5447

Ipr1 modified BCG as a novel vaccine induces stronger immunity than BCG against tuberculosis infection in mice

Authors:
- Yuwei Wang
- Chun Yang
- Yonglin He
- Xingxing Zhan
- Lei Xu
View Affiliations

Affiliations: Department of Laboratory Medicine, Chongqing Hospital of Traditional Chinese Medicine, Chongqing 400021, P.R. China, Department of Microbiology, Chongqing Medical University, Chongqing 400016, P.R. China, Department of Pediatrics, Chongqing Medical University, Chongqing 400016, P.R. China
Published online on: June 27, 2016 https://doi.org/10.3892/mmr.2016.5447
Pages: 1756-1764

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tuberculosis is a major challenge to global public health. However, the Bacille Calmette‑Guérin (BCG), the only vaccine available against tuberculosis, has been questioned for the low protective effect. The present study used the mouse gene intracellular pathogen resistance I (Ipr1) gene to alter the current BCG vaccine and evaluated its immunity effect against tuberculosis. This study also investigated the intrinsic relationships of Ipr1 and innate immunity. The reformed BCG (BCGi) carrying the Ipr1 gene was constructed. The mice were intranasally challenged with the M. tuberculosis H37Rv strain after vaccination with BCGi. Protection efficacy of the vaccine was assessed by the organ coefficient, bacterial load and pathological changes in the lung. The differential expression of 113 immune‑related genes between BCGi and BCG groups were detected by an oligo microarray. According to the results of organ coefficient, bacterial load and pathological changes in the organization, BCGi had been shown to have stronger protective effects against M. tuberculosis than BCG. The oligo microarray and reverse transcription‑quantitative polymerase chain reaction further revealed that the Ipr1 gene could upregulate the expression of 13 genes, including a >3‑fold increase in Toll‑like receptor (TLR)4 and 10‑fold increase in surfactant protein D (sftpd). The two genes not only participate in innate immunity against pathogens, but also are closely interrelated. Ipr1 could activate the TLR4 and sftpd signaling pathway and improve the innate immunity against tuberculosis, therefore Ipr1 modified BCG may be a candidate vaccine against M. tuberculosis.

View Figures

View References

1	Global tuberculosis control: surveillance, planning, financing. (WHO report 2007). Geneva: World Health Organization (WHO/HTM/TB/2007.376);
2	Dos Santos JL, Lima MM, Trindade AB, Carnavalli F, Melchior AC and Chin CM: Tuberculosis: Challenges to improve the treatment. Curr Clin Pharmacol. 2013.Epub ahead of print.
3	Montagnani C, Chiappini E, Galli L and de Martino M: Vaccine against tuberculosis: What's new? BMC Infect Dis. 14(Suppl 1): S22014. View Article : Google Scholar : PubMed/NCBI
4	Martin C: Tuberculosis vaccines: Past, present and future. Curr Opin Pulm Med. 12:186–191. 2006. View Article : Google Scholar : PubMed/NCBI
5	Pan H, Yan BS, Rojas M, Shebzukhov YV, Zhou H, Kobzik L, Higgins DE, Daly MJ, Bloom BR and Kramnik I: Ipr1 gene mediates innate immunity to tuberculosis. Nature. 434:767–772. 2005. View Article : Google Scholar : PubMed/NCBI
6	Wang YW, Xu L, Zhang L, He YL, Yang C and Huang AL: Construction the recombinant BCG targeting delivering IprI into macrophages: A new strategy of vaccine against tuberculosis. African Journal of Microbiology Research. 7:533–540. 2013.
7	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar
8	Fang R, Li X, Li J, Wu J, Shen X, Gui X, DeRiemer K, Liu L, Mei J and Gao Q: Mixed infections of Mycobacterium tuberculosis in tuberculosis patients in Shanghai, China. Tuberculosis (Edinb). 88:469–73. 2008. View Article : Google Scholar
9	Bellamy R: Genetic susceptibility to tuberculosis. Clin Chest Med. 26:233–246. 2005. View Article : Google Scholar : PubMed/NCBI
10	Png E, Alisjahbana B, Sahiratmadja E, Marzuki S, Nelwan R, Adnan I, van de Vosse E, Hibberd M, van Crevel R, Ottenhoff TH and Seielstad M: Polymorphisms in SP110 are not associated with pulmonary tuberculosis in Indonesians. Infect Genet Evol. 12:1319–1323. 2012. View Article : Google Scholar : PubMed/NCBI
11	Lei X, Zhu H, Zha L and Wang Y: SP110 gene polymorphisms and tuberculosis susceptibility: A systematic review and meta-analysis based on 10 624 subjects. Infect Genet Evol. 12:1473–1480. 2012. View Article : Google Scholar : PubMed/NCBI
12	Liang L, Zhao YL, Yue J, Liu JF, Han M, Wang H and Xiao H: Association of SP110 gene polymorphisms with susceptibility to tuberculosis in a Chinese population. Infect Genet Evol. 11:934–939. 2011. View Article : Google Scholar : PubMed/NCBI
13	Kramnik I: Genetic dissection of host resistance to Mycobacterium tuberculosis: The sst1 locus and the Ipr1 gene. Curr Top Microbiol Immunol. 321:123–148. 2008.PubMed/NCBI
14	Orme IM, McMurray DN and Belisle JT: Tuberculosis vaccine development: Recent progress. Trends Microbiol. 9:115–118. 2001. View Article : Google Scholar : PubMed/NCBI
15	Quesniaux V, Fremond C, Jacobs M, Parida S, Nicolle D, Yeremeev V, Bihl F, Erard F, Botha T, Drennan M, et al: Toll-like receptor pathways in the immune responses to mycobacteria. Microbes Infect. 6:946–959. 2004. View Article : Google Scholar : PubMed/NCBI
16	Jung SB, Yang CS, Lee JS, Shin AR, Jung SS, Son JW, Harding CV, Kim HJ, Park JK, Paik TH, et al: The mycobacterial 38-kilodalton glycolipoprotein antigen activates the mitogen-activated protein kinase pathway and release of proinflammatory cytokines through Toll-like receptors 2 and 4 in human monocytes. Infect Immun. 74:2686–2696. 2006. View Article : Google Scholar : PubMed/NCBI
17	Ospelt C and Gay S: TLRs and chronic inflammation. Int J Biochem Cell Biol. 42:495–505. 2010. View Article : Google Scholar
18	Hartl D and Griese M: Surfactant protein D in human lung diseases. Eur J Clin Invest. 36:423–435. 2006. View Article : Google Scholar : PubMed/NCBI
19	Haczku A: Protective role of the lung collectins surfactant protein A and surfactant protein D in airway inflammation. J Allergy Clin Immunol. 122:861–879. 2008. View Article : Google Scholar : PubMed/NCBI
20	Forbes LR and Haczku A: SP-D and regulation of the pulmonary innate immune system in allergic airway changes. Clin Exp Allergy. 40:547–562. 2010. View Article : Google Scholar : PubMed/NCBI
21	Gaynor CD, McCormack FX, Voelker DR, McGowan SE and Schlesinger LS: Pulmonary surfactant protein A mediates enhanced phagocytosis of Mycobacterium tuberculosis by a direct interaction with human macrophages. J Immunol. 155:5343–5351. 1995.PubMed/NCBI
22	Weikert LF, Edwards K, Chroneos ZC, Hager C, Hoffman L and Shepherd VL: SP-A enhances uptake of bacillus Calmette-Guerin by macrophages through a specific SP-A receptor. Am J Physiol. 272:L989–L995. 1997.PubMed/NCBI
23	Chiba H, Sano H, Iwaki D, Murakami S, Mitsuzawa H, Takahashi T, Konishi M, Takahashi H and Kuroki Y: Rat mannose-binding protein a binds CD14. Infect Immun. 69:1587–1592. 2001. View Article : Google Scholar : PubMed/NCBI
24	Ohya M, Nishitani C, Sano H, Yamada C, Mitsuzawa H, Shimizu T, Saito T, Smith K, Crouch E and Kuroki Y: Human pulmonary surfactant protein D binds the extracellular domains of Toll-like receptors 2 and 4 through the carbohydrate recognition domain by a mechanism different from its binding to phosphatidylinositol and lipopolysaccharide. Biochemistry. 45:8657–8664. 2006. View Article : Google Scholar : PubMed/NCBI
25	Guillot L, Balloy V, McCormack FX, Golenbock DT, Chignard M and Si-Tahar M: Cutting edge: The immunostimulatory activity of the lung surfactant protein-A involves toll-like receptor 4. J Immunol. 168:5989–5992. 2002. View Article : Google Scholar : PubMed/NCBI
26	Zhang L, Ikegami M, Crouch EC, Korfhagen TR and Whitsett JA: Activity of pulmonary surfactant protein-D (SP-D) in vivo is dependent on oligomeric structure. J Biol Chem. 276:19214–19219. 2001. View Article : Google Scholar : PubMed/NCBI
27	van Iwaarden JF, Shimizu H, Van Golde PH, Voelker DR and Van Golde LM: Rat surfactant protein D enhances the production of oxygen radicals by rat alveolar macrophages. Biochem J. 286:5–8. 1992. View Article : Google Scholar : PubMed/NCBI